Roche Holding AG said IMvigor211, the original confirmatory study for the accelerated approval, didn't meet its primary endpoint. Tecentriq had been granted that approval in 2016 based on the results from the IMvigor210 study. "Roche Withdraws Bladder-Cancer Indication for Tecentriq in US," at 0629 GMT on Monday, incorrectly said the IMvigor210 study didn't meet its primary endpoint.

 

(END) Dow Jones Newswires

March 09, 2021 07:02 ET (12:02 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Roche (QX) Charts.